Summary
The AI response makes multiple claims about indications/efficacy and drug comparisons (statins vs aspirin; Coumadin/Eliquis stroke prevention; P2Y12 inhibitor list includes Savaysa; relative effectiveness of P2Y12 inhibitors vs aspirin) that are not supported by the provided FDA label excerpt for Aspirin and Extended-Release Dipyridamole Capsules, and therefore are largely unsupported.
Category Scores
Accurate Statements
Aspirin and extended-release dipyridamole capsules reduce the risk of stroke in patients who have had transient ischemia of the brain (TIA) or completed ischemic stroke due to thrombosis.
INDICATIONS AND USAGE: “indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis.”; CLINICAL STUDIES: ESPS2 reduced risk of stroke vs placebo and comparator arms.
Unsupported Statements
Aspirin is taken to prevent heart attacks.
No such heart-attack indication is supported by the provided prescribing information excerpt.
Aspirin is taken to prevent strokes.
The provided label excerpt specifies use to reduce risk of stroke in patients with TIA or completed ischemic stroke due to thrombosis; general 'prevent strokes' is broader than supported.
Statins lower cholesterol levels and prevent cardiovascular disease.
The provided label excerpt is for Aspirin and Extended-Release Dipyridamole Capsules and does not support statin indications or effects.
Statins are shown to be just as effective as aspirin in reducing the risk of heart attacks and strokes.
No statin vs aspirin comparative effectiveness is supported by the provided label excerpt.
Coumadin and Eliquis can be used to prevent strokes.
No information in the provided label excerpt supports stroke prevention indications for warfarin (Coumadin) or apixaban (Eliquis).
Coumadin and Eliquis can be used to prevent blood clots.
No information in the provided label excerpt supports blood-clot prevention indications for warfarin or apixaban.
Plavix (clopidogrel) prevents platelets from clumping together to form blood clots.
No such mechanism/indication details for clopidogrel are supported by the provided label excerpt.
Effient (prasugrel) prevents platelets from clumping together to form blood clots.
No such mechanism/indication details for prasugrel are supported by the provided label excerpt.
Plavix is slightly more effective than aspirin in preventing blood clots and heart attacks.
No comparative effectiveness statement between clopidogrel and aspirin is supported by the provided label excerpt.
Effient is slightly more effective than aspirin in preventing blood clots and heart attacks.
No comparative effectiveness statement between prasugrel and aspirin is supported by the provided label excerpt.
P2Y12 inhibitors include Brilinta (ticagrelor) and Savaysa (edaroten).
The provided label excerpt does not support listing of P2Y12 inhibitors or the inclusion of 'Savaysa (edaroten)'.
P2Y12 inhibitors are more effective than aspirin in preventing heart attacks and strokes.
No comparative effectiveness between P2Y12 inhibitors and aspirin is supported by the provided label excerpt.
P2Y12 inhibitors are more effective than aspirin especially in patients with high risk factors.
No subgroup/risk-factor comparative effectiveness statement is supported by the provided label excerpt.
P2Y12 inhibitors can increase the risk of bleeding.
No warnings/precautions for P2Y12 inhibitors are supported by the provided label excerpt.
P2Y12 inhibitors can increase the risk of other side effects.
No warnings/precautions for P2Y12 inhibitors are supported by the provided label excerpt.
Contradictions
Important Omissions
The response does not provide any label-supported dosage, administration technique, or interchangeability/specific administration instructions for Aspirin and Extended-Release Dipyridamole Capsules (e.g., dosing frequency, swallowing whole, with/without food, and not interchangeable with individual components).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Most statements concern other drugs (statins, Coumadin/eliquis, Plavix/Effient, P2Y12 inhibitors) and broad comparative claims not supported by the provided prescribing information excerpt; relying on these could mislead treatment selection.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Major Noncompliance
Primary Issue
Numerous unsupported claims about indications/mechanisms/comparative effectiveness for drugs other than (and not covered by) the supplied Aspirin + Extended-Release Dipyridamole Capsules label excerpt.
Suggested Improvement
Limit claims strictly to the provided label-supported indication and label-supported efficacy statements for Aspirin and Extended-Release Dipyridamole Capsules, and remove or replace unsupported statements about other drug classes/agents and comparative effectiveness.